Get the Stockscreener App
32.93
0.09%
-0.03
After Hours:
33.25
0.32
+0.97%
Exelixis Inc Stock (EXEL) Latest News
Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001 - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight - MSN
Smith Group Asset Management LLC Acquires Shares of 9,150 Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exelixis's SWOT analysis: cancer drug maker's stock faces patent cliff, pipeline promise - Investing.com
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis patent discloses USP1 inhibitors for cancer - BioWorld Online
Exelixis Sets Date for Major 2024 Performance Reveal: Key Details Inside - StockTitan
Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - Inkl
EXEL: Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - StockNews.com
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges By Investing.com - Investing.com Australia
Exelixis (EXEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Exelixis (NASDAQ:EXEL) Given Equal Weight Rating at Stephens - Defense World
Exelixis (NASDAQ:EXEL) Given New $43.00 Price Target at Truist Financial - Defense World
Exelixis (NASDAQ:EXEL) Rating Increased to Overweight at Morgan Stanley - Defense World
Exelixis (NASDAQ:EXEL) Given “Buy” Rating at HC Wainwright - Defense World
Exelixis downgraded by Oppenheimer to perform - MSN
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight By Investing.com - Investing.com Canada
Morgan Stanley Upgrades Exelixis (EXEL) - MSN
Stifel maintains hold rating, $30 target on Exelixis stock - MSN
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform - Nasdaq
Exelixis (NASDAQ:EXEL) Price Target Raised to $43.00 - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism - MSN
Exelixis (NASDAQ:EXEL) Receives "Equal Weight" Rating from Stephens - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism By Investing.com - Investing.com UK
H.C. Wainwright maintains $40 target on Exelixis stock - Investing.com India
HC Wainwright Reaffirms "Buy" Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Exelixis stock holds Market Outperform rating, $41 target - MSN
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Exelixis, Inc. (NASDAQ:EXEL) Stake Boosted by Nisa Investment Advisors LLC - Defense World
Park Avenue Securities LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Nisa Investment Advisors LLC Increases Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
8,301 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by DGS Capital Management LLC - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Exchange Traded Concepts LLC - MarketBeat
UMB Bank n.a. Purchases 553 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis's SWOT analysis: cabozantinib strength, pipeline potential drive stock - MSN
Exelixis (NASDAQ:EXEL) Rating Lowered to “Market Perform” at Oppenheimer - Defense World
Exelixis (NASDAQ:EXEL) Stock Price Down 5.6%Here's Why - MarketBeat
Exelixis Cancer Drug Trial Shows Promising Survival Benefits in Colorectal Cancer Study - StockTitan
Exelixis falls after ASCO releases colorectal cancer data - MSN
Exelixis Cancer Drug Shows 50% Risk Reduction in Phase 3 GI NET Trial - StockTitan
Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? - GuruFocus.com
Exelixis Faces Critical Crossroads: What’s Next? - Jomfruland.net
Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns - Yahoo Finance
Exelixis (NASDAQ:EXEL) Downgraded to "Market Perform" Rating by Oppenheimer - MarketBeat
Inspire Investing LLC Purchases 7,331 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Merit Financial Group LLC Invests $437,000 in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Merit Financial Group LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis stock rating cut by Oppenheimer, price target to $33 from $41 - MSN
JMP Securities Reaffirms "Market Outperform" Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
JMP Securities maintains Exelixis stock with $41 target - MSN
Exelixis (NASDAQ:EXEL) Given Buy Rating at Guggenheim - MarketBeat
Exelixis falls 8% on abstract for colorectal cancer candidate zanzalintinib - MSN
Exelixis's SWOT analysis: cabozantinib growth and zanzalintinib potential buoy stock - MSN
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):